O
HRTX icon

OrbiMed’s Heron Therapeutics HRTX Stock Holding History

OrbiMed’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.85M Buy
+9,816,940
New +$11.4M 0.16% 84
2024
Q3 		– Sell
-6,512,866
Closed -$22.8M – 126
2024
Q2 		$22.8M Sell
6,512,866
-3,598,684
-36% -$11.1M 0.45% 57
2024
Q1 		$28M Buy
10,111,550
+4,182,959
+71% +$10.5M 0.51% 53
2023
Q4 		$10.1M Buy
5,928,591
+5,125,891
+639% +$5.64M 0.2% 77
2023
Q3 		$827K Hold
802,700
– – 0.02% 121
2023
Q2 		$931K Hold
802,700
– – 0.02% 121
2023
Q1 		$1.21M Buy
+802,700
New +$2.01M 0.02% 115
2022
Q4 		– Sell
-1,123,000
Closed -$4.74K – 122
2022
Q3 		$4.74K Buy
+1,123,000
New +$4.39M 0.09% 106
2021
Q1 		– Sell
-1,191,846
Closed -$25.2M – 170
2020
Q4 		$25.2M Hold
1,191,846
– – 0.22% 91
2020
Q3 		$17.7M Buy
1,191,846
+531,426
+80% +$8.29M 0.22% 89
2020
Q2 		$9.71M Buy
660,420
+123,000
+23% +$2.02M 0.14% 102
2020
Q1 		$6.31M Buy
+537,420
New +$10.1M 0.11% 97
2019
Q2 		– Sell
-1,069,000
Closed -$26.1M – 132
2019
Q1 		$26.1M Sell
1,069,000
-331,300
-24% -$8.67M 0.4% 61
2018
Q4 		$36.3M Sell
1,400,300
-114,200
-8% -$3.14M 0.67% 47
2018
Q3 		$47.9M Buy
1,514,500
+199,400
+15% +$7.43M 0.58% 55
2018
Q2 		$51.1M Buy
1,315,100
+175,300
+15% +$5.58M 0.61% 50
2018
Q1 		$31.5M Buy
1,139,800
+489,800
+75% +$11.1M 0.39% 66
2017
Q4 		$11.8M Hold
650,000
– – 0.15% 101
2017
Q3 		$10.5M Hold
650,000
– – 0.1% 106
2017
Q2 		$9M Hold
650,000
– – 0.09% 99
2017
Q1 		$9.75M Buy
+650,000
New +$9M 0.11% 98

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

OrbiMed's HRTX Position: Q1 2026 in Review

OrbiMed opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 9,816,940 shares worth $7.85M. The stake represents 0.16% of the portfolio and ranks #84 among its holdings. This is a return to the name: OrbiMed previously reported a position in HRTX as recently as Q2 2024.

OrbiMed first reported a position in HRTX in Q1 2017 and has held it in 21 quarters since. The position peaked at $51.1M in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • OrbiMed held 9,816,940 shares of Heron Therapeutics worth $7.85M as of Q1 2026.
  • Heron Therapeutics was a new OrbiMed position in Q1 2026.
  • Heron Therapeutics made up 0.16% of OrbiMed's portfolio in Q1 2026, its #84 holding.
  • OrbiMed first reported a position in Heron Therapeutics in Q1 2017 and has held it in 21 quarters since.
  • OrbiMed's Heron Therapeutics position peaked at $51.1M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.